Arca Biopharma | ABIO - Cash And Equivalent


Arca Biopharma reported $46.93M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 12.04B 2.91B Mar/2026
Arca Biopharma USD 46.93M 44.32M Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
Brainstorm Cell Therapeutics USD 5K 819K Sep/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Capricor Therapeutics USD 287.85M 268.34M Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 129.84M 7.32M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Laboratory Of America USD 981.1M 448.8M Mar/2026
Myriad Genetics USD 149.6M 4.2M Dec/2025
Otsuka Holdings JPY 534.64B 123.53B Dec/2025
Pfizer USD 1.7B 561M Mar/2026
United Therapeutics USD 1.56B 217M Dec/2025